Skip to main content

Master of Public Health

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.

AUTHORS

De Montalembert M , Abboud MR , Fiquet A , Inati A , Lebensburger JD , Kaddah N , Mokhtar G , Piga A , Halasa N , Inusa B , Rees DC , Heath PT , Telfer P , Driscoll C , Al Hajjar S , Tozzi A , Jiang Q , Emini EA , Gruber WC , Gurtman A , Scott DA , . Pediatric blood & cancer. 2015 3 23; ().

ABSTRACT

A large population of older children with sickle cell disease (SCD) is currently vaccinated with only 23-valent pneumococcal polysaccharide vaccine (PPSV23). In immunocompetent adults, PPSV23 vaccination reduces immune responses to subsequent vaccination with a pneumococcal vaccine. The 13-valent pneumococcal conjugate vaccine (PCV13), which addresses this limitation, may offer an advantage to this population at high risk of pneumococcal disease.

A large population of older children with sickle cell disease (SCD) is currently vaccinated with only 23-valent pneumococcal polysaccharide vaccine (PPSV23). In immunocompetent adults, PPSV23 vaccination reduces immune responses to subsequent vaccination with a pneumococcal vaccine. The 13-valent pneumococcal conjugate vaccine (PCV13), which addresses this limitation, may offer an advantage to this population at high risk of pneumococcal disease.

Tags: